Scancell Holdings plc (AIM: SCLP), the late-stage immuno-oncology company developing active immunotherapies for difficult-to-treat cancers, has provided a wide-ranging clinical and corporate update on 19 November 2026. The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to inzitagene plasmivec in advanced melanoma, complementing an existing Fast Track Designation. The company also confirmed its global Phase 3 registrational trial remains on track for a first-patient-in date in December 2026, subject to completion of a planned NASDAQ listing to finance the trial's execution.

Key Points

  • Scancell Holdings plc (AIM: SCLP) — late-stage clinical immuno-oncology company based in the UK
  • FDA grants RMAT designation to inzitagene plasmivec (iSCIB1+) for advanced melanoma, adding to existing Fast Track Designation
  • Phase 3 global registrational trial of inzitagene plasmivec targeted to begin December 2026; NASDAQ listing on track for late 2026 or early 2027
  • Investors will be watching for NASDAQ listing completion, Phase 3 first-patient-in confirmation, and interim SCOPE trial data expected in H1 2027

FDA RMAT Designation Unlocks Accelerated Pathway for inzitagene plasmivec in Advanced Melanoma

The FDA's RMAT designation grants Scancell the combined benefits of Fast Track and Breakthrough Therapy designations, including intensive FDA guidance on efficient drug development and eligibility for rolling review, priority review, and accelerated approval if relevant criteria are met. The announcement states Scancell will request an initial comprehensive multidisciplinary RMAT meeting with the FDA to discuss the Phase 3 trial design and manufacturing strategy. The World Health Organization has also formally assigned "inzitagene plasmivec" as the International Nonproprietary Name for iSCIB1+, providing the candidate with a single globally recognised non-proprietary designation used by regulators and scientific publications worldwide.

Phase 2 SCOPE Trial Data Shows 87% Overall Survival at 24 Months for iSCIB1+ Cohort

The latest data cut from the Phase 2 SCOPE trial, analysed on 12 November 2026, shows overall survival at 24 months of 82% across combined SCIB1 and iSCIB1+ cohorts (n=80), with iSCIB1+ alone reaching 87%. Progression-free survival for the combined cohorts stands at 65% at 24 months in the HLA-target population, rising to 71% for the iSCIB1+ cohort. The complete response rate has improved to 28% for combined cohorts and 31% for the iSCIB1+ Cohort 3. The announcement notes that the standard of care comparator, ipilimumab and nivolumab, achieved a 24-month PFS of 41.5% in the CheckMate 067 study. More mature PFS data and interim overall survival data from SCOPE are expected in H1 2027.

ModiFY Phase 2 Trial Links Modi-1 Immune Response to Longer Progression-Free Survival in Renal Cell Carcinoma

New data from the fully recruited Phase 2 ModiFY trial of Modi-1 in renal cell carcinoma (RCC) show that 46% of patients mounted a vaccine-specific immune response to Modi-1's citrullinated peptides. Those immune responders demonstrated a six-month PFS rate of 75% versus 50% in non-responders (p=0.0025), an objective response rate of 58% versus 36%, and a median PFS not reached at 22 months' follow-up compared with six months in non-responders. The trial's overall RCC cohort (n=43) reported an objective response rate of 48% and a median PFS of 7.8 months. The announcement states no toxicity beyond that expected with ipilimumab and nivolumab was observed, and no autoimmune disease was detected.

NASDAQ Listing and Neuphoria Business Combination Sought to Fund Phase 3 Execution

Scancell confirmed it remains on track to complete a NASDAQ listing in late 2026 or early 2027 through a proposed business combination with Neuphoria Therapeutics Inc., with a Registration Statement on Form F-4 filed with the SEC on 9 October 2026. Completion of the transaction is intended to provide financing for the global Phase 3 registrational trial of inzitagene plasmivec in advanced melanoma, which has already received IND clearance from the FDA and a Clinical Trial Authorisation from the UK MHRA. Investors may be watching for Neuphoria stockholder approval of the transaction and confirmation that Phase 3 enrolment has commenced as planned.